Home » Newsletters » BioWorld Science

BioWorld Science

July 27, 1998

View Archived Issues

Redox-oriented prophylactic therapy improves quality of life in cancer patients

Phase II study finds IL-2 fusion protein effective but toxic in patients with psoriasis

Phosphonic acids that block EAA receptors: new series from Novartis

Zeneca presents peptides for modifying autoimmune responses as in RA

Antitumor bis(acridinecarboxamide) and bis(phenazinecarboxamide) derivatives

European phase III testing under way with Cerus' platelet pathogen inactivation system

Boehringer Ingelheim reports preliminary findings of ECASS II trial

Troponin I inhibits retinal angiogenesis in animal studies

Micronetics, Praxis enter into reorganization agreement

Conjugated linoleic acid prevents, reverses atherosclerosis in animal models

FDA approves new dosing regimen for SB's amoxicillin

Synsorb announces commencement of U.S. phase II trials for CDAD Rx

First SELEX compound from NeXstar heads for clinical trials in ARMD

Allergan and Warner-Lambert collaborate on retinoid compounds for diabetes, metabolic disorders

Titan commences phase II trials of small-molecule anticancer agent

Efficacy of Demeter's Peptidyl MIM compounds demonstrated in animal models of prostate cancer

Combination of angiostatin and radiation results in significantly increased tumor growth inhibition

Long-term leflunomide prevents allergic sensitization in rats

Longer treatment with EMLA associated with increased pain relief during cleansing of leg ulcers

SB-209670 improves ischemia-reperfusion injury in canine lung allografts

First report of neural stem cells forming functioning dopamine-producing neurons in culture

AxyS elucidates 3-D structure of cathepsin S

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...